SOHO21
REVEAL is the largest prospective and contemporary cohort of patients with PV in the United States.
The OPTIC study evaluated a response-based dose-reduction strategy to optimize the benefit-risk of a TKI in CP-CML.
In patients with previously treated CLL and SLL, pirtobrutinib was safe and associated with high rates of response.
Farhad Ravandi, MD, and Jeffrey Lancet, MD, squared off on this clinical quandary.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.